TipRanks
GlaxoSmithKline (MX:GSKN)
:GSKN
Mexico Market

GlaxoSmithKline (GSKN) Drug Pipeline

0 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Gsk3862995b
Pulmonary Disease, Chronic Obstructive
Phase I
Recruiting
A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Two GSK3862995B Formulations in Healthy Participants
Aug 24, 2026
―
Standard Of Care, Gsk5784283
Pulmonary Disease, Chronic Obstructive
Phase III
Not Yet Recruiting
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)
Aug 19, 2026
Standard Of Care, Gsk5784283
Asthma
Phase III
Not Yet Recruiting
A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-1)
Aug 19, 2026
Standard Of Care, Gsk5784283
Pulmonary Disease, Chronic Obstructive
Phase III
Not Yet Recruiting
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
Aug 19, 2026
Gsk5784283
Asthma
Phase I
Recruiting
A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283
Jul 14, 2026
Adjuvanted Rsvpref3 Vaccine, Adjuvanted Rzv Vaccine
Cardiovascular Disease
Phase II
Not Yet Recruiting
A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events
Jul 14, 2026
Efimosfermin Alfa
Metabolic Dysfunction-associated Steatohepatitis
Phase III
Recruiting
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Jul 10, 2026
Efimosfermin Alfa
Metabolic Dysfunction-associated Steatohepatitis
Phase III
Recruiting
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Jul 09, 2026
Bevacizumab, Mocertatug Rezetecan
Ovarian Neoplasms
Phase III
Not Yet Recruiting
Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]
Jul 01, 2026
Carboplatin, Bevacizumab, Gemcitabine, Paclitaxel, Pegylated Liposomal Doxorubicin, Mocertatug Rezetecan
Ovarian Neoplasms
Phase III
Not Yet Recruiting
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
Jun 29, 2026

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does GlaxoSmithKline (GSKN) have in its pipeline
      GSKN is currently developing the following drugs: Gsk3862995b, Standard Of Care, Gsk5784283, Standard Of Care, Gsk5784283. These drug candidates are in various stages of clinical development as the company works toward FDA approval.